Lexaria Bioscience shareholders approve the appointment of four directors

() (OTCMKTS:LXRP) reported a successful annual general meeting Friday, noting all matters were approved, including the appointment of four directors. 

The firm said directors appointed included: Chris Bunka, John Docherty, Nicholas Baxter and Ted McKechnie. The firm noted Davidson & LLP has been appointed as auditor. 

READ: Lexaria Bioscience crafts new DehydraTECH innovation, files patents

The firm noted shareholders also approved executive compensation.

Lexaria has developed and out-licenses its delivery technology, which promotes healthier ingestion methods and lower overall dosing. Its DehydraTECH technology is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time. The firm acquired its technology in 2014. 

Lexaria's technology provides boosts in intestinal absorption rates and more rapid bloodstream delivery for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The firm has patents pending in more than 40 countries.

Shares of Lexaria Bioscience were at C$1.10 on Friday. 

Contact Katie Lewis at [email protected]